drugset / Trial / NCT04624295
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
Phase 4
Recruiting
294 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Affiliated Hospital of Jiaxing University · collabHuzhou Central Hospital · collabJinhua Central Hospital · collabLishui Country People's Hospital · collabNingbo Medical Center Lihuili Hospital · collabNingbo No.2 Hospital · collabShaoxing People's Hospital · collabShenzhen Second People's Hospital · collabTaizhou Hospital · collabThe Affiliated Hospital of Xuzhou Medical University · collabThe Fourth Affiliated Hospital of Zhejiang University School of Medicine · collabThe Second Affiliated Hospital of Jiaxing University · collabWenzhou Central Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2025-12-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | — | — |